TTrialPathMatch Me to Trials
← Back to trials
RecruitingObesity

First in Human Study in Subjects With Obesity, But Otherwise Healthy

Eligible age

18–65 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.

Sponsor: NeuroBo Pharmaceuticals Inc.

You may qualify if…

  • ✓ 1. Willing and able to provide informed consent prior to initiation of any study specific procedures/activities.
  • ✓ 2. Males and females ≥18 to \<=65 years of age, at the time of signing informed consent, who have been diagnosed with obesity, defined by BMI.
  • ✓ 3. Except for obesity, otherwise healthy or with stable, well controlled obesity-related conditions as determined by the investigator based on a medical evaluation including physical exam, medical history, laboratory tests, and ECGs.
  • ✓ 4. Body mass index (BMI) ≥ 30.0 kg/m2 to 45.0 kg/m2 (Obesity to be confirmed by Caliper test showing body fat percentage with the average or above the average level).
  • ✓ 5. Has maintained a stable body weight during the 3 months prior to Screening (\<5% body weight change).
  • ✓ 6. Willing to maintain current diet and physical activity regimen.
  • ✓ SAD Cohorts (Be willing to eat a standard diet while in the Clinical Research Unit).
  • ✓ MAD Cohorts (Be willing to eat a standard diet while in the Clinical Research Unit). If appetite decreases, participants may not maintain their current diet.

You may not qualify if…

  • ✕ 1. History or clinical evidence of diabetes mellitus, including a fasting glucose of ≥ 120 mg/dL and/or HbA1c ≥ 6.5% at Screening.
  • ✕ 2. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
  • ✕ 3. History of cholecystectomy \<= 6 months prior to screening.
  • ✕ 4. Subjects with screening calcitonin level of ≥15 pg/mL (calcitonin levels will be monitored during the study).
  • ✕ 5. Triglycerides ≥500 mg/dL at Screening.
  • ✕ 6. History of pancreatitis.
  • ✕ 7. Have a medical history or current evidence of clinically significant cardiac condition as evidenced by any of the following at Screening :
  • ✕ QTc at Screening from locally generated data of \>450 msec in males or \>470 msec in females or history of long QT syndrome

Where it's recruiting

Florida

Miami

Source: ClinicalTrials.gov · NCT06252220 · last updated 2026-04-09

First in Human Study in Subjects With Obesity, But Otherwise Healthy · TrialPath